Format
Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 1 to 20 of 301

1.

Risk of major bleeding in patients with venous thromboembolism treated with rivaroxaban or with heparin and vitamin K antagonists.

Di Nisio M, Ageno W, Rutjes AW, Pap AF, Büller HR.

Thromb Haemost. 2016 Jan 27;115(2):424-32. doi: 10.1160/TH15-06-0474. Epub 2015 Oct 29.

PMID:
26511068
2.

Antithrombotic Therapy Practices in Older Adults Residing in the Long-Term Care Setting.

Oo W, Kozikowski A, Stein J, Lolis J, Pekmezaris R, Makaryus AN, Wolf-Klein G.

South Med J. 2015 Jul;108(7):432-6. doi: 10.14423/SMJ.0000000000000312.

PMID:
26192941
3.

The safety and efficacy of use of low-molecular-weight heparin in pediatric neurosurgical patients.

Gonda DD, Fridley J, Ryan SL, Briceño V, Lam SK, Luerssen TG, Jea A.

J Neurosurg Pediatr. 2015 Sep;16(3):329-34. doi: 10.3171/2015.1.PEDS14489. Epub 2015 Jun 12.

PMID:
26067336
4.

Intracranial hemorrhage in patients with brain metastases treated with therapeutic enoxaparin: a matched cohort study.

Donato J, Campigotto F, Uhlmann EJ, Coletti E, Neuberg D, Weber GM, Zwicker JI.

Blood. 2015 Jul 23;126(4):494-9. doi: 10.1182/blood-2015-02-626788. Epub 2015 May 18.

PMID:
25987658
5.

Timing for deep vein thrombosis chemoprophylaxis in traumatic brain injury: an evidence-based review.

Abdel-Aziz H, Dunham CM, Malik RJ, Hileman BM.

Crit Care. 2015 Mar 24;19:96. doi: 10.1186/s13054-015-0814-z. Review.

6.
7.

New oral anti-coagulants: Implications for neurosurgery.

Vakharia VN, Tai D, Marcus H, Vakharia NN, Nandi D.

Br J Neurosurg. 2015 Apr;29(2):182-8. doi: 10.3109/02688697.2014.997667. Epub 2015 Jan 29.

PMID:
25633803
8.

Is prophylactic anticoagulation for deep venous thrombosis common practice after intracerebral hemorrhage?

Prabhakaran S, Herbers P, Khoury J, Adeoye O, Khatri P, Ferioli S, Kleindorfer DO.

Stroke. 2015 Feb;46(2):369-75. doi: 10.1161/STROKEAHA.114.008006. Epub 2015 Jan 8.

9.

The economic implications of switching to rivaroxaban from enoxaparin plus vitamin K antagonist in the treatment of venous thromboembolism.

Patel AA, Ogden K, Mody SH, Bookhart B.

J Med Econ. 2015 May;18(5):323-32. doi: 10.3111/13696998.2014.1001850. Epub 2015 Jan 5.

PMID:
25557176
10.

The risks of thromboembolism vs. recurrent gastrointestinal bleeding after interruption of systemic anticoagulation in hospitalized inpatients with gastrointestinal bleeding: a prospective study.

Sengupta N, Feuerstein JD, Patwardhan VR, Tapper EB, Ketwaroo GA, Thaker AM, Leffler DA.

Am J Gastroenterol. 2015 Feb;110(2):328-35. doi: 10.1038/ajg.2014.398. Epub 2014 Dec 16. Erratum in: Am J Gastroenterol. 2015 Mar;110(3):480.

PMID:
25512338
11.

The safety of low molecular-weight heparin after blunt liver and spleen injuries.

Rostas JW, Manley J, Gonzalez RP, Brevard SB, Ahmed N, Frotan MA, Mitchell E, Simmons JD.

Am J Surg. 2015 Jul;210(1):31-4. doi: 10.1016/j.amjsurg.2014.08.023. Epub 2014 Oct 13.

PMID:
25510476
12.

Venous thromboembolism in cancer patients.

Deng A, Galanis T, Graham MG.

Hosp Pract (1995). 2014 Dec;42(5):24-33. doi: 10.3810/hp.2014.12.1156. Review.

PMID:
25485915
13.

Factor XI antisense oligonucleotide for prevention of venous thrombosis.

Büller HR, Bethune C, Bhanot S, Gailani D, Monia BP, Raskob GE, Segers A, Verhamme P, Weitz JI; FXI-ASO TKA Investigators.

N Engl J Med. 2015 Jan 15;372(3):232-40. doi: 10.1056/NEJMoa1405760. Epub 2014 Dec 7.

14.

[Perioperative control of vitamin K antagonists in elective surgery].

Revigliono JI, Cornavaca T, Becerra F, Albertini R, Contreras AE, Tabares A.

Medicina (B Aires). 2014;74(5):385-90. Spanish.

15.

Safety and efficacy of edoxaban, an oral factor Xa inhibitor, versus enoxaparin for thromboprophylaxis after total knee arthroplasty: the STARS E-3 trial.

Fuji T, Wang CJ, Fujita S, Kawai Y, Nakamura M, Kimura T, Ibusuki K, Ushida H, Abe K, Tachibana S.

Thromb Res. 2014 Dec;134(6):1198-204. doi: 10.1016/j.thromres.2014.09.011. Epub 2014 Sep 21.

PMID:
25294589
16.

Thromboprophylaxis after minimally invasive total knee arthroplasty: a comparison of rivaroxaban and enoxaparin.

Yen SH, Lin PC, Kuo FC, Wang JW.

Biomed J. 2014 Jul-Aug;37(4):199-204. doi: 10.4103/2319-4170.125627.

17.

Coagulopathy in liver diseases: complication or therapy?

Bianchini M, De Pietri L, Villa E.

Dig Dis. 2014;32(5):609-14. doi: 10.1159/000360514. Epub 2014 Jul 14. Review.

PMID:
25034295
18.

Predicting the risk of venous thromboembolism in patients hospitalized with heart failure.

Mebazaa A, Spiro TE, Büller HR, Haskell L, Hu D, Hull R, Merli G, Schellong SW, Spyropoulos AC, Tapson VF, De Sanctis Y, Cohen AT.

Circulation. 2014 Jul 29;130(5):410-8. doi: 10.1161/CIRCULATIONAHA.113.003126. Epub 2014 Jun 26.

19.

Bleeding risk of patients with acute venous thromboembolism taking nonsteroidal anti-inflammatory drugs or aspirin.

Davidson BL, Verheijen S, Lensing AW, Gebel M, Brighton TA, Lyons RM, Rehm J, Prins MH.

JAMA Intern Med. 2014 Jun;174(6):947-53. doi: 10.1001/jamainternmed.2014.946.

PMID:
24733305
20.

Benefit-risk assessment of rivaroxaban versus enoxaparin for the prevention of venous thromboembolism after total hip or knee arthroplasty.

Levitan B, Yuan Z, Turpie AG, Friedman RJ, Homering M, Berlin JA, Berkowitz SD, Weinstein RB, DiBattiste PM.

Vasc Health Risk Manag. 2014 Mar 26;10:157-67. doi: 10.2147/VHRM.S54714. eCollection 2014.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk